Summit Therapeutics annual r&d spending
2018
2019
2020
2021
2022
2023
2024
2025
Summit Therapeutics R&D Spending Growth & History (SMMT)
Summit Therapeutics's r&d spending was $537.7M for fiscal 2025.
View full Summit Therapeutics company overviewSummit Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $537.7M | $386.9M | +256.60% |
| 2024 | 2024-12-31 | $150.8M | $91.3M | +153.53% |
| 2023 | 2023-12-31 | $59.5M | $7.5M | +14.37% |
| 2022 | 2022-12-31 | $52.0M | −$33.4M | −39.08% |
| 2021 | 2021-12-31 | $85.4M | $32.1M | +60.21% |
| 2020 | 2020-12-31 | $53.3M | $13.5M | +33.82% |
| 2019 | 2019-12-31 | $39.8M | — | — |
| 2018 | 2019-01-31 | $52.0M | — | — |
Summit Therapeutics quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $157.7M | −$50.3M | −24.17% |
| Q1 2026 | 2026-03-31 | $132.6M | $81.4M | +158.69% |
| Q4 2025 | 2025-12-31 | $147.3M | $95.9M | +186.66% |
| Q3 2025 | 2025-09-30 | $131.1M | $93.4M | +247.51% |
| Q2 2025 | 2025-06-30 | $208.0M | $177.2M | +575.44% |
| Q1 2025 | 2025-03-31 | $51.3M | $20.4M | +66.05% |
| Q4 2024 | 2024-12-31 | $51.4M | $26.6M | +107.07% |
| Q3 2024 | 2024-09-30 | $37.7M | $22.4M | +146.19% |
| Q2 2024 | 2024-06-30 | $30.8M | $21.3M | +225.87% |
| Q1 2024 | 2024-03-31 | $30.9M | $21.0M | +212.38% |
| Q4 2023 | 2023-12-31 | $24.8M | $19.4M | +360.71% |
| Q3 2023 | 2023-09-30 | $15.3M | −$1.7M | −10.12% |
| Q2 2023 | 2023-06-30 | $9.5M | $443,000 | +4.92% |
| Q1 2023 | 2023-03-31 | $9.9M | −$10.7M | −51.92% |
| Q4 2022 | 2022-12-31 | $5.4M | −$17.7M | −76.69% |
| Q3 2022 | 2022-09-30 | $17.0M | −$2.9M | −14.51% |
| Q2 2022 | 2022-06-30 | $9.0M | −$14.9M | −62.35% |
| Q1 2022 | 2022-03-31 | $20.6M | $2.2M | +11.85% |
| Q4 2021 | 2021-12-31 | $23.1M | $10.0M | +76.88% |
| Q3 2021 | 2021-09-30 | $19.9M | $6.2M | +45.29% |
| Q2 2021 | 2021-06-30 | $23.9M | $10.4M | +76.27% |
| Q1 2021 | 2021-03-31 | $18.4M | $5.5M | +42.34% |
| Q4 2020 | 2020-12-31 | $13.1M | — | — |
| Q3 2020 | 2020-09-30 | $13.7M | $3.8M | +37.94% |
| Q2 2020 | 2020-06-30 | $13.6M | — | — |
| Q1 2020 | 2020-03-31 | $12.9M | — | — |
| Q3 2019 · Sep 30 | 2019-09-30 | $10.0M | — | — |
Summit Therapeutics r&d spending trends
Over the last five fiscal years, Summit Therapeutics's r&d spending increased from $53.3M to $537.7M, a change of $484.4M. The latest reported quarter, Q2 2026, shows $157.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Summit Therapeutics source filings ↗